Market revenue in 2024 | USD 6,857.4 million |
Market revenue in 2030 | USD 13,820.8 million |
Growth rate | 12.4% (CAGR from 2024 to 2030) |
Largest segment | Large molecule |
Fastest growing segment | Large Molecule |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule, Large Molecule |
Key market players worldwide | Baxter International Inc, Catalent Inc, Recipharm, Fresenius SE & Co KGaA, Cipla Ltd DR, Vetter Pharma-Fertigung, Aenova Group, Unither Pharmaceuticals, Famar, Sorrento Therapeutics Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to sterile injectable contract manufacturing market will help companies and investors design strategic landscapes.
Large molecule was the largest segment with a revenue share of 67.07% in 2024. Horizon Databook has segmented the North America sterile injectable contract manufacturing market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America sterile injectable contract manufacturing market , including forecasts for subscribers. This continent databook contains high-level insights into North America sterile injectable contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account